Intellia Therapeutics(NTLA)
Focus: Intellia Therapeutics is a public biotech company focused on therapeutic gene editing using CRISPR technology, headquartered in Cambridge, MA with a pipeline spanning rare genetic diseases and oncology.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
12-5 this month
Cooling — net -5 jobs in 30d
4 added, 9 removed. Slower than typical.
Should You Work at Intellia Therapeutics?
AI assessmentHigh-upside gene-therapy play with legitimate clinical catalysts, but burn rate and tightening cash position create execution risk; best for risk-tolerant professionals betting on CRISPR's clinical validation.
Why Work Here
- Pioneering CRISPR platform with 10 active pipeline programs across multiple therapeutic areas including Phase 3 candidates (NTLA-2002 in HAE, NTLA-2001 in ATTR cardiomyopathy).
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$36M
Pipeline & Clinical Trials
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyClinical Trials (1)
NCT05697861Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
N/AHelp build intelligence for Intellia Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.